Evidence map›Paper›PMID 36291163›Full record

ArticleCells2022

Modulation of Neutrophil Activity by Soluble Complement Cleavage Products-An In-Depth Analysis.

Lisa Wohlgemuth, Alexander Elias Paul Stratmann, Frederik Münnich, Stefan Bernhard, Bertram Dietrich Thomaß, Finn Münnich, Adam Omar Khalaf Mohamed, Marco Mannes, Christoph Quirin Schmidt, Kristina Nilsson Ekdahl and 5 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 2 countries.

Lisa WohlgemuthInstitute of Clinical and Experimental Trauma Immunology, University Hospital Ulm, 89081 Ulm, Germany.ORCID 0000-0001-5795-812X
Alexander Elias Paul StratmannInstitute of Clinical and Experimental Trauma Immunology, University Hospital Ulm, 89081 Ulm, Germany.
Frederik MünnichInstitute of Clinical and Experimental Trauma Immunology, University Hospital Ulm, 89081 Ulm, Germany.
Stefan BernhardInstitute of Clinical and Experimental Trauma Immunology, University Hospital Ulm, 89081 Ulm, Germany.
Bertram Dietrich ThomaßInstitute of Clinical and Experimental Trauma Immunology, University Hospital Ulm, 89081 Ulm, Germany.
Finn MünnichInstitute of Clinical and Experimental Trauma Immunology, University Hospital Ulm, 89081 Ulm, Germany.
Adam Omar Khalaf MohamedInstitute of Clinical and Experimental Trauma Immunology, University Hospital Ulm, 89081 Ulm, Germany.
Marco MannesInstitute of Clinical and Experimental Trauma Immunology, University Hospital Ulm, 89081 Ulm, Germany.
Christoph Quirin SchmidtInstitute of Experimental and Clinical Pharmacology, Toxicology and Pharmacology of Natural Products, University of Ulm Medical Center, 89081 Ulm, Germany.
Kristina Nilsson EkdahlRudbeck Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, 75185 Uppsala, Sweden.ORCID 0000-0001-7888-1571
Bo NilssonRudbeck Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, 75185 Uppsala, Sweden.
Michael FaulerInstitute of General Physiology, Ulm University, 89081 Ulm, Germany.ORCID 0000-0002-7371-849X
Karl Josef FöhrDepartment of Anesthesiology and Intensive Care Medicine, University Hospital Ulm, 89081 Ulm, Germany.ORCID 0000-0003-0116-6750
Markus Huber-LangInstitute of Clinical and Experimental Trauma Immunology, University Hospital Ulm, 89081 Ulm, Germany.
David Alexander Christian MessererInstitute of Clinical and Experimental Trauma Immunology, University Hospital Ulm, 89081 Ulm, Germany.ORCID 0000-0002-0834-038X
University Hospital Ulm · DEHeidelberg University · DEUniversität Ulm · DEUppsala University · SEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEUniversity Hospital Augsburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cellular and fluid phase-innate immune responses of many diseases predominantly involve activated neutrophil granulocytes and complement factors. However, a comparative systematic analysis of the early impact of key soluble complement cleavage products, including anaphylatoxins, on neutrophil granulocyte function is lacking. Neutrophil activity was monitored by flow cytometry regarding cellular (electro-)physiology, cellular activity, and changes in the surface expression of activation markers. The study revealed no major effects induced by C3a or C4a on neutrophil functions. By contrast, exposure to C5a or C5a des-Arg stimulated neutrophil activity as reflected in changes in membrane potential, intracellular pH, glucose uptake, and cellular size. Similarly, C5a and C5a des-Arg but no other monitored complement cleavage product enhanced phagocytosis and reactive oxygen species generation. C5a and C5a des-Arg also altered the neutrophil surface expression of several complement receptors and neutrophil activation markers, including C5aR1, CD62L, CD10, and CD11b, among others. In addition, a detailed characterization of the C5a-induced effects was performed with a time resolution of seconds. The multiparametric response of neutrophils was further analyzed by a principal component analysis, revealing CD11b, CD10, and CD16 to be key surrogates of the C5a-induced effects. Overall, we provide a comprehensive insight into the very early interactions of neutrophil granulocytes with activated complement split products and the resulting neutrophil activity. The results provide a basis for a better and, importantly, time-resolved and multiparametric understanding of neutrophil-related (patho-)physiologies.

Indexed as

AnaphylatoxinsNeutrophilsComplement C5a, des-ArginineComplement System ProteinsGlucoseReactive Oxygen SpeciesAnaphylatoxinsComplement C5a, des-ArginineComplement System ProteinsGlucoseReactive Oxygen Speciesanaphylatoxinscomplement systeminflammationinnate immunityneutrophils

Identifiers

PMID36291163
PMCPMC9600402
OpenAlexW4306948239

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.